Ionis Pharmaceuticals Inc
$ 74.83
0.07%
22 Apr - close price
- Market Cap 12,353,059,000 USD
- Current Price $ 74.83
- High / Low $ 75.44 / 74.00
- Stock P/E N/A
- Book Value 3.00
- EPS -2.38
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.71 %
- 52 Week High 86.74
- 52 Week Low 28.79
About
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
Analyst Target Price
$98.32
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-10-29 | 2025-07-30 | 2025-05-05 | 2025-02-19 | 2024-11-06 | 2024-08-01 | 2024-05-07 | 2024-02-21 | 2023-11-02 | 2023-08-09 | 2023-05-03 |
| Reported EPS | -1.1481 | -0.8 | 0.7 | -0.9245 | -0.4304 | -0.95 | -0.45 | -0.98 | -0.06 | -1.03 | -0.6 | -0.87 |
| Estimated EPS | -1.33 | -1.22 | -0.24 | -1.01 | -0.8444 | -1.16 | -0.92 | -1.05 | -0.83 | -1.04 | -0.9 | -0.91 |
| Surprise | 0.1819 | 0.42 | 0.94 | 0.0855 | 0.414 | 0.21 | 0.47 | 0.07 | 0.77 | 0.01 | 0.3 | 0.04 |
| Surprise Percentage | 13.6767% | 34.4262% | 391.6667% | 8.4653% | 49.0289% | 18.1034% | 51.087% | 6.6667% | 92.7711% | 0.9615% | 33.3333% | 4.3956% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.86 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.186 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IONS
2026-04-21 20:38:57
Ionis Pharmaceuticals announced positive new data from its pivotal study of zilganersen for Alexander disease (AxD) at the 2026 American Academy of Neurology (AAN) annual meeting. The study demonstrated that zilganersen provides potential treatment benefits across multiple AxD symptom domains, including statistically significant stabilization of gait speed, and improved gross motor function in younger children. The drug also showed a favorable safety profile and is currently under Priority Review with the FDA, with a PDUFA date set for September 22, 2026.
2026-04-21 17:09:22
Canaccord Genuity has initiated coverage on Ionis Pharmaceuticals (IONS) with a "Buy" rating and a price target of $110. Despite this positive analyst outlook, Ionis Pharmaceuticals is deemed 50.5% overvalued by GuruFocus's GF Valueâ„¢ at a current price of $74.58. The company has a GF Scoreâ„¢ of 70/100, indicating solid overall performance with strong growth potential but weaker financial strength and profitability, and has seen significant insider selling worth $70.7 million in the last three months.
2026-04-21 16:09:22
Ionis Pharmaceuticals Inc. (IONS) has initiated the ASCEND clinical trial for ION337, an experimental drug aimed at treating Dravet syndrome, a rare and severe form of epilepsy. This Phase 1-2 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intrathecally-administered ION337 in children with the condition. The move strengthens Ionis's pipeline in neurological diseases and addresses a high unmet medical need.
2026-04-21 15:09:22
Ionis Pharmaceuticals (IONS) announced positive results from its pivotal trial for zilganersen, a treatment for Alexander disease, showing stabilization of gait speed in older patients and improved motor skills in younger patients. While this marks a significant breakthrough for a condition with no approved therapies, the company faces financial challenges, including negative earnings and significant insider selling, despite its strong growth prospects. The GF Scoreâ„¢ for IONS is 70/100, indicating moderate overall performance.
2026-04-21 12:10:07
Canaccord Genuity has initiated coverage on Ionis Pharmaceuticals (IONS) with a Buy rating and a price target of $110. This indicates an optimistic outlook from the firm regarding the company's future performance.
2026-04-21 12:09:22
Ionis Pharmaceuticals announced that its drug, Zilganersen 50 mg, met its primary endpoint in a clinical trial for Alexander Disease, demonstrating stabilization of gait speed in patients aged 5 and older at week 61. This positive outcome highlights the drug's potential for treating this rare neurodegenerative disorder. The news was published by Reuters and follows other recent positive developments for Ionis, including priority review status for Zilganersen's New Drug Application by the FDA.
